P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS

• Francesca Palandri,
• Lucia Masarova,
• Srdan Verstovsek,
• Ruben Mesa,
• Claire Harrison,
• Gautam Sajeev,
• Boris Gorsh,
• Ryan Simpson,
• Sang Cho,
• Zhaohui Wang,
• Catherine Ellis,
• Sean Conlon,
• James Signorovitch

Affiliations

Francesca Palandri

1 Universita Di Bologna, Bologna, Italy

Lucia Masarova

2 The University of Texas MD Anderson Cancer Center, Houston, United States

Srdan Verstovsek

2 The University of Texas MD Anderson Cancer Center, Houston, United States

Ruben Mesa

3 Wake Health, Winston-Salem, United States

Claire Harrison

4 Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom

Gautam Sajeev

5 Analysis Group, Boston, United States

Boris Gorsh

6 GSK plc, Philadelphia, United States

Ryan Simpson

5 Analysis Group, Boston, United States

Sang Cho

5 Analysis Group, Boston, United States

Zhaohui Wang

6 GSK plc, Philadelphia, United States

Catherine Ellis

6 GSK plc, Philadelphia, United States

Sean Conlon

7 GSK plc, Reading, United Kingdom

James Signorovitch

5 Analysis Group, Boston, United States